High levels of pathogen resistance are rendering current antibiotics obsolete. Coupled with insufficient investment in discovering new treatments, multidrug-resistant infections are an increasingly urgent public health concern. To curb the growth of antibiotic resistance and prevent major...

This article uses panel data to investigate the extent of income-related inequity in the likelihood of visiting a General Practitioner (GP), specialist, dentist and hospital among individuals aged 65 years and over in the UK. The probability of accessing health care is predicted with separate...

In view of increasing cost pressures, this paper aims to provide guidance to national EU policy-makers faced with the challenge of reconciling financial sustainability of health systems with the safeguarding of the key underlying values of these health systems; namely universal coverage,...

A generally accepted view is that it is more efficient and ethical if global pharmaceutical prices vary according to countries? relative income. To understand manufacturers? pricing strategies, we compared average pharmaceutical prices in fourteen middle-income countries to those in three...

Pharmaceutical parallel trade in the European Union is a large and growing phenomenon, and hope has been expressed that it has the potential to reduce prices paid by health insurance and consumers and substantially to raise overall welfare. In this paper we examine the phenomenon empirically,...

This paper investigates how regulation impinges on the launch strategies of international pharmaceutical corporations for new molecules and generics across the main OECD markets during 1960-2008. Comprehensive IMS data is used to analyze the international diffusion of 845 molecules from 14...

While recent research has explored the phenomenon of drug parallel trade in regulated environments such as the European Union (EU), or the European Economic Area, little is known about the mechanisms that explain its origin or the role of the distribution chain in exporting and importing...

Quality of care is qualified as a main determinant of the demand for voluntary private health insurance (PHI) in National Health Systems (NHS). This paper provides new evidence on the influence of the quality gap between public and private health insurance and other demand determinants in the...

Generic competition in the pharmaceutical market is an effective cost-containment mechanism that improves static efficiency and stimulates pharmaceutical innovation. There is no prior study that has empirically analysed the relative delays in adoption of generic competition. This paper aims to...

The issue of the nature of the altruism inherent in blood donation and the perverse effects of financial rewards for blood and/or organ donation has been recently revisited in the economic literature with limited consensus. As Titmuss (1970) famously pointed out, providing monetary incentives to...